


## SUPPLEMENTARY APPENDIX

# **Clinical guidelines for burosumab in the treatment of XLH in children and adolescents: British Paediatric and Adolescent Bone group recommendations**

### **Authors and Affiliation**

Raja Padidela<sup>1</sup>, Moira S. Cheung<sup>2</sup>, Vrinda Saraff<sup>3</sup>, Poonam Dharmaraj<sup>4</sup>

<sup>1</sup>Royal Manchester Children's Hospital and Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK, <sup>2</sup>Evelina London Children's Hospital, <sup>3</sup>Birmingham Women's and Children's Hospital, Birmingham, UK, <sup>4</sup>Alder Hey Children's NHS Foundation Trust, Liverpool, UK

### **Corresponding author's postal and email address:**

Dr Raja Padidela, Consultant Paediatric Endocrinologist and Metabolic Bone Diseases, Dept of Paediatric Endocrinology, Manchester University NHS Foundation Trust Hospital, Oxford Road, Manchester M13 9WL

 raja.padidela@mft.nhs.uk

### **Short title:**

XLH guidelines - BPABG recommendations

### **Key Words:**

XLH, hypophosphataemia, burosumab, NICE, BPABG

## **Appendix 1 – Members of European Reference Network for Rare Bone Disease (ERN BOND) in UK**

- Alder Hey Children’s NHS Foundation Trust
- Birmingham Children's Hospital NHS Foundation Trust
- Bristol University Hospital NHS Foundation Trust
- Central Manchester University Hospitals NHS Foundation Trust
- Great Ormond Street Hospital for Children NHS Foundation Trust
- Guy's and St Thomas' NHS Foundation Trust
- Manchester University Hospitals NHS Foundation Trust
- Newcastle upon Tyne Hospitals NHS Foundation Trust
- Oxford University Hospitals NHS Foundation Trust
- Royal National Orthopaedic Hospital NHS Trust
- Sheffield Children’s NHS Foundation Trust
- Sheffield Teaching Hospitals NHS Foundation Trust
- University Hospitals Southampton NHS Foundation Trust